Screener
Rhythm Pharmaceuticals, Inc. RYTM Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Research and development | 41,725 | 36,973 |
| Selling, general, and administrative | 63,591 | 39,087 |
| Total costs and expenses | 112,473 | 79,708 |
| Loss from operations | (52,361) | (47,004) |
| Other income (expense): | ||
| Other income (expense), net | (1,704) | (644) |
| Interest expense | (4,583) | (5,409) |
| Interest income | 3,554 | 3,639 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s operating income?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported operating income of -$52.36M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s operating income changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s operating income decreased by 11.4% year-over-year, from -$47M to -$52.36M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s operating income?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s operating income has grown at a 3.1% compound annual growth rate (CAGR), from -$170.06M to -$192.02M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude